AstraZeneca: all 4,196 studies
Page 37 of 42. Open to participants first (299), then studies with results posted, then the rest; newest registration first within each.
- Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children OutpatientsCompletedNCT00660114
- To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)CompletedNCT00659841Phase 3
- To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)CompletedNCT00659750Phase 3
- A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With AsthmaCompletedNCT00659659Phase 1
- Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)CompletedNCT00659594Phase 3
- Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)CompletedNCT00659503Phase 3
- Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)CompletedNCT00659048Phase 3
- To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)CompletedNCT00658918Phase 3
- Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis TurbuhalerCompletedNCT00658255Phase 2
- Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate CancerCompletedNCT00657904Phase 3
- Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery DiseaseCompletedNCT00657527Phase 3
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusCompletedNCT00657189Phase 2
- 48-wk Open Label Phase IIIb to Evaluate Efficacy and SafetyCompletedNCT00654602Phase 3
- STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose RangesCompletedNCT00654537Phase 3
- COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome SubjectsCompletedNCT00654485Phase 3
- IIIb 6 Week Open Label Multicentre Rosuvastatin & SimvastatinCompletedNCT00654446Phase 3
- Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb HypercholesterolemiaCompletedNCT00654407Phase 3
- Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic SubjectsCompletedNCT00654394Phase 3
- OLE Study to Evaluate Safety / Efficacy of ZD4522CompletedNCT00654303Phase 3
- Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)CompletedNCT00654225Phase 3
- Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)CompletedNCT00654173Phase 3
- Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)CompletedNCT00653965Phase 3
- Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)CompletedNCT00653744Phase 3
- Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 WeeksCompletedNCT00653588Phase 3
- Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mgCompletedNCT00653445Phase 3
- Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEMCompletedNCT00652392Phase 3
- Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5CompletedNCT00652002Phase 3
- Titratable Dosing in Moderate to Severe AsthmaticsCompletedNCT00651768Phase 3
- Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5CompletedNCT00651651Phase 3
- Symbicort in Asthmatic Children - SEEDLINGCompletedNCT00651547Phase 3
- Symbicort Onset of Action 1CompletedNCT00646620Phase 3
- Atlantis SymbicortCompletedNCT00646594Phase 3
- Long-Term Safety of Symbicort in Asthmatic Children - SAPLINGCompletedNCT00646529Phase 3
- Gemini Symbicort pMDICompletedNCT00646516Phase 3
- Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUTCompletedNCT00646321Phase 3
- Symbicort Onset of Action 2CompletedNCT00646009Phase 3
- Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been HealedCompletedNCT00644735Phase 4
- Quality Of Life While Receiving FaslodexCompletedNCT00643513
- New Version Pulmicort Turbuhaler USA AdultsCompletedNCT00642187Phase 3
- New Version Pulmicort Turbuhaler USA ChildrenCompletedNCT00642161Phase 3
- Adults With Moderate to Severe AsthmaCompletedNCT00642122Phase 3
- Factorial Study of Metoprolol Succinate TOPROL-XL (324A)CompletedNCT00642096Phase 3
- New Nasal Applicator / New Formulation - User StudyCompletedNCT00641979Phase 2
- Inhaled Steroid Treatment as Regular Therapy in Early AsthmaCompletedNCT00641914Phase 4
- Assess the Efficacy and Safety of Rhinocort AquaCompletedNCT00641693Phase 2
- Rhinocort Aqua Versus Placebo and Fluticasone PropionateCompletedNCT00641680Phase 3
- A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive EsophagitisCompletedNCT00641602Phase 4
- Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, ChildrenCompletedNCT00641472Phase 4
- Varicella Vaccination With PulmicortCompletedNCT00641446Phase 4
- Quality of Life Validation in LaryngitisCompletedNCT00641264Phase 4
- Children, Perennial Allergic Rhinitis (PAR), l-t GrowthCompletedNCT00641212Phase 4
- Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast CancerCompletedNCT00638391
- Barrett's Esophagus - 315 - 3 Way Cross OverCompletedNCT00637988Phase 4
- Casodex - Nolvadex CombinationCompletedNCT00637871Phase 2
- Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)CompletedNCT00637845Phase 4
- Barrett's Esophagus - 315 - 3 Way Cross-OverCompletedNCT00637559Phase 4
- ZAP, US. Zomig for Appropriate for Primary CareCompletedNCT00637286Phase 4
- Gynecomastia Extension StudyCompletedNCT00637182Phase 3
- Study of AZD8931 in Patients With Advanced Solid MalignanciesCompletedNCT00637039Phase 1
- Ph II Early BC Pre-Surgical Biologic StudyCompletedNCT00637026Phase 2
- Casodex 150-mg Compassionate Use Trial for Subjects With Prostate CancerNo longer availableNCT00636259
- Open-Label Extension of Other SZ1839 (Iressa) TrialsCompletedNCT00635973Phase 3
- Open Label Trial to Assess Iressa in Prostate Cancer PatientsCompletedNCT00635856Phase 2
- Second Line Breast Cancer TrialCompletedNCT00635713Phase 3
- Open, Randomized, Two Way Crossover 40mg, Orally and IntravenouslyCompletedNCT00635414Phase 4
- Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)CompletedNCT00634712Phase 3
- Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)CompletedNCT00634400Phase 3
- Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)CompletedNCT00634309Phase 3
- Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERDCompletedNCT00634023
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is ContinuedCompletedNCT00633672Phase 3
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US OnlyCompletedNCT00633412Phase 3
- Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic TumoursCompletedNCT00633269Phase 1
- IRESSA™ (Gefitinib) in Breast Cancer PatientsCompletedNCT00632723Phase 2
- Ulcer Prevention IICompletedNCT00629928Phase 3
- An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)CompletedNCT00629564Phase 4
- Prevention of Gastric UlcersCompletedNCT00629512Phase 3
- Adult Asthmatics and Acid RefluxCompletedNCT00628953Phase 2
- Chronic Posterior Laryngitis With Suspected Laryngopharyngeal RefluxCompletedNCT00628667Phase 4
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)CompletedNCT00628342Phase 4
- A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in InfantsWithdrawnNCT00628303Phase 3
- A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWithdrawnNCT00627627Phase 1/2
- A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)CompletedNCT00626535Phase 3
- Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and ivCompletedNCT00626262Phase 4
- Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)CompletedNCT00625495Phase 4
- A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using PatientsCompletedNCT00625274Phase 4
- Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With AnastrozoleCompletedNCT00623519
- Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino PatientsCompletedNCT00622323
- Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid TumoursCompletedNCT00621725Phase 1
- Seroquel- Agitation Associated With DementiaCompletedNCT00621647Phase 3
- Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer PatientsCompletedNCT00621361Phase 1
- Atacand (Candesartan) Real Life StudyCompletedNCT00620178
- Efficacy and Tolerability of Zolmitriptan Nasal SprayCompletedNCT00617747Phase 3
- Naïve HIV POC Monotherapy TrialCompletedNCT00617526Phase 2
- Schizophrenic Patients Taking Part in Integrated Care ProgramTerminatedNCT00617214
- A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult PatientsCompletedNCT00613652Phase 1
- Symbicort in Chronic Obstruktive Pulmonary DiseaseCompletedNCT00612976
- A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 DiabetesCompletedNCT00612794Phase 1
- Symptoms and Endoscopic Results in Consideration of PretreatmentCompletedNCT00612404
- Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care ConditionsCompletedNCT00612027
- Symbicort in Chronic Obstructive Pulmonary DiseaseCompletedNCT00611520